The molecular and cellular basis of Apert syndrome.

Cellular survival: a play in three Akts. Genes Dev (1999) 17.05

Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci (2001) 6.66

Activation and signaling of the p38 MAP kinase pathway. Cell Res (2005) 5.48

Mechanisms and functions of p38 MAPK signalling. Biochem J (2010) 4.59

Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci (2004) 4.40

Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet (1995) 4.01

Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocr Rev (1993) 2.76

Visceral anomalies in the Apert syndrome. Am J Med Genet (1993) 2.26

RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet (2007) 2.22

Birth prevalence study of the Apert syndrome. Am J Med Genet (1992) 2.10

Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol (2000) 2.08

Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development (2005) 1.93

Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Am J Hum Genet (2002) 1.88

Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome. Am J Hum Genet (1996) 1.86

Analysis of phenotypic features and FGFR2 mutations in Apert syndrome. Am J Hum Genet (1995) 1.85

A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone (2003) 1.50

Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways. J Cell Physiol (2008) 1.46

Pilosebaceous abnormalities in Apert's syndrome. Arch Dermatol (1970) 1.46

Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development (2007) 1.38

Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J Clin Invest (1998) 1.30

A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone (2008) 1.29

Mammalian phospholipase C. Annu Rev Physiol (2012) 1.28

Genotype-phenotype correlation for nucleotide substitutions in the IgII-IgIII linker of FGFR2. Hum Mol Genet (1997) 1.25

Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology. Dev Biol (2009) 1.24

The oral manifestations of Apert syndrome. J Craniofac Genet Dev Biol (1992) 1.23

Regulation of human cranial osteoblast phenotype by FGF-2, FGFR-2 and BMP-2 signaling. Histol Histopathol (2002) 1.20

Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. J Biol Chem (2008) 1.18

Keratinocyte growth factor is an important endogenous mediator of hair follicle growth, development, and differentiation. Normalization of the nu/nu follicular differentiation defect and amelioration of chemotherapy-induced alopecia. Am J Pathol (1995) 1.17

Understanding the molecular basis of Apert syndrome. Plast Reconstr Surg (2005) 1.17

Fibroblast growth factor expression in the postnatal growth plate. Bone (2006) 1.13

Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice. BMC Dev Biol (2010) 1.11

Respiratory complications during anaesthesia in Apert syndrome. Paediatr Anaesth (2001) 1.09

Fgfr mRNA isoforms in craniofacial bone development. Bone (2003) 1.08

Apert and Crouzon syndromes: clinical findings, genes and extracellular matrix. J Craniofac Surg (2005) 1.07

A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem (2004) 1.07

A clinical study of the craniofacial features in Apert syndrome. Int J Oral Maxillofac Surg (1996) 1.03

Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders. Am J Pathol (1999) 1.02

Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis. J Bone Miner Res (2001) 1.01

Rare mutations of FGFR2 causing apert syndrome: identification of the first partial gene deletion, and an Alu element insertion from a new subfamily. Hum Mutat (2009) 0.98

Skeletal abnormalities in the Apert syndrome. Am J Med Genet (1993) 0.97

The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation. Exp Cell Res (2000) 0.97

From shape to cells: mouse models reveal mechanisms altering palate development in Apert syndrome. Dis Model Mech (2013) 0.92

Sustained platelet-derived growth factor receptor alpha signaling in osteoblasts results in craniosynostosis by overactivating the phospholipase C-gamma pathway. Mol Cell Biol (2008) 0.92

Role of FGFR2-signaling in the pathogenesis of acne. Dermatoendocrinol (2009) 0.92

Functional characterization of a novel FGFR2 mutation, E731K, in craniosynostosis. J Cell Biochem (2012) 0.92

Anti-acne agents attenuate FGFR2 signal transduction in acne. J Invest Dermatol (2009) 0.91

Sebaceous gland response in man to the administration of testosterone, delta-4-androstenedione, and dehydroisoandrosterone. J Invest Dermatol (1969) 0.90

The p38α MAPK positively regulates osteoblast function and postnatal bone acquisition. Cell Mol Life Sci (2012) 0.90

The primary site of the acrocephalic feature in Apert Syndrome is a dwarf cranial base with accelerated chondrocytic differentiation due to aberrant activation of the FGFR2 signaling. Bone (2010) 0.88

Increased osteoblast apoptosis in apert craniosynostosis: role of protein kinase C and interleukin-1. Am J Pathol (2001) 0.88

The study of abnormal bone development in the Apert syndrome Fgfr2+/S252W mouse using a 3D hydrogel culture model. Bone (2008) 0.87

Cutaneous manifestations of Apert syndrome. Am J Med Genet (1995) 0.85

Oral manifestations in Apert syndrome: case presentation and a brief review of the literature. Rom J Morphol Embryol (2010) 0.85

Increased EFG- and PDGFalpha-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis. Hum Mol Genet (2010) 0.85

The mouse seminal vesicle shape mutation is allelic with Fgfr2. Development (2007) 0.83

Apert syndrome. Int J Dermatol (2006) 0.82

Apert syndrome with fused thalami. Fetal Pediatr Pathol (2012) 0.81

Enhancement of fibronectin fibrillogenesis and bone formation by basic fibroblast growth factor via protein kinase C-dependent pathway in rat osteoblasts. Mol Pharmacol (2004) 0.81

Activating (P253R, C278F) and dominant negative mutations of FGFR2: differential effects on calvarial bone cell proliferation, differentiation, and mineralization. Connect Tissue Res (2003) 0.81

Apert syndrome in a newborn infant without craniosynostosis. J Craniofac Surg (2012) 0.81

Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts. J Cell Physiol (2012) 0.77

FGFR2 mutation confers a less drastic gain of function in mesenchymal stem cells than in fibroblasts. Stem Cell Rev (2012) 0.77

Mouse models of Apert syndrome. Childs Nerv Syst (2012) 0.77

Activity of 5-alpha-reductase and 17-beta-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology (1998) 0.77

Brachycephaly and syndactyly: Apert's syndrome. Indian J Dermatol Venereol Leprol (2008) 0.76

Apert syndrome. Indian J Dermatol Venereol Leprol (2010) 0.76

Apert syndrome with septum pellucidum agenesis. Singapore Med J (2007) 0.76

Effects of targeted modulation of miR-762 on expression of the IFITM5 gene in Saos-2 cells. Intractable Rare Dis Res (2014) 0.76